Overall verdict
Buy
6.5/10
1-year performance
+38.24%
Score breakdown
Up 38.2% over 1 year, 78% of the 52-week range.
Strongest: Financial strength 10.0/10. Weakest: Growth 2.0/10.
27 analysts, target +0.1% vs the price.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema ;
myopic choroidal neovascularization ; diabetic retinopathy ; neovascular glaucoma ; retinopathy of prematurity ; Dupixent injection to treat atopic dermatitis and asthma ; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma ; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH) ; and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA ;
Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system ; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases ; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor ;
and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. The company was incorporated in 1988 and is based in Tarrytown, New York.
Sector
Health Care
Industry
Biotechnology
Primary listing
Nasdaq
United States
CEO
Leonard Schleifer
Founded
1988
Employees
15 410
Revenue / employee
930 753 USD
Next earnings
October 30, 2026 (Q3 2026)
Institutional holders
- BlackRock, Inc.8.70%
- VANGUARD CAPITAL MANAGEMENT LLC6.33%
- Dodge & Cox4.65%
- STATE STREET CORP4.62%
- Invesco Ltd.3.76%
- JPMORGAN CHASE & CO3.60%
- VANGUARD PORTFOLIO MANAGEMENT LLC3.03%
- FRANKLIN RESOURCES INC2.65%
- GEODE CAPITAL MANAGEMENT, LLC2.51%
- Other institutions47.21%
- Rest of the register12.93%
1331 13F filings as of June 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
859.34 USD
52-week low
541.00 USD
1-year performance
38.24%
Rising
Year-to-date performance
3.56%
Rising
Drawdown
-8.27%
Mild pullback
Position in the 52-week range
78% of range
Against the world ETF
Over 17 years, from September 2009 to August 2026, the share did not do better than the world ETF once risk is accounted for. It earned more, but shaking 3.3 times harder: for the risk taken, the ETF paid better.
10,000 € placed at the end of September 2009 are worth today
| Regeneron | 525 397 € |
| World ETF | 74 620 € |
| S&P 500 | 123 025 € |
| Risk-free placement | 11 288 € |
The risk
- Shaking:the share moves 3.3 times as much as the world ETF.
- Worst fall:-61 % between August 2024 and June 2025. 10,000 € placed at the top fell to 3 916 €. The world ETF, at worst: -34 %. The share has not returned to its high yet.
Regeneron earned 7 times as much as the world ETF since 2009
Value of 10,000 euros placed at the end of September 2009, dividends reinvested, in euros
- Regeneron: 525 397 €
- World ETF: 74 620 €
- S&P 500: 123 025 €
- Risk-free placement: 11 288 €
Based on past performance. This is not a recommendation.
Range: 922.47 USD - 932.38 USD (3 methods agree)
The price implies growth of 6.22% per year; the company grows at 6.33%.
Gross margin 81.5%, net margin 27.9%, ROIC 13.0%, ROE 14.0%.
Net margin
27.86%
High
Sector -15.62%|S&P 12.97%
Gross margin
81.46%
Fair
Return on equity (ROE)
14.04%
Fair
Sector -19.73%|S&P 16.52%
Return on invested capital (ROIC)
13.05%
Fair
Free cash flow margin (FCF)
24.21%
High
Profit-to-cash conversion (FCF conversion)
0.87x
High
Margin stability
9.8 pts
Uneven
Revenue to net income
Growth
2.0/10Revenue up 16.7% over 1 year, 11.0% a year over 5, EPS 6.3% a year over 5.
Revenue (trailing 12 months)
15.5Md USD
Revenue growth (1y)
16.73%
Hyper-growth
Revenue growth (3y)
17.83%
Solid
EPS growth (1y)
-4.52%
Declining
EPS CAGR (5y)
6.33%
Low
EPS revisions (3 months)
16.98%
Sharply revised up
Valuation
6.6/10P/E 19.5x, forward P/E 18.0x, EV/EBITDA 17.9x, PEG 3.08. The multiple sits in the 56th percentile of its own 5-year history.
P/E (TTM)
19.5x
Fair
Sector 29.9x|S&P 23.0x
Forward P/E
18.0x
Cheap
EV / EBITDA
17.9x
Fair
Sector 23.4x|S&P 14.5x
PEG
3.08
Very expensive
Sector 1.05|S&P 0.86
Fair value (reverse DCF)
927.43 USD
Undervalued
P/E vs its own 5-year history
among the 44% highest valuations
In line with its history
Market cap
82.6Md USD
Financial strength
10.0/10Cash covers 295.8% of the debt, net debt/EBITDA -1.3x.
Net debt / EBITDA
-1.3x
Net cash
Gearing (net debt / equity)
-16.71%
Net cash
Cash
8.0Md USD
Cash / market cap
9.70%
Solid
Cash / total debt
295.75%
Net cash
Interest coverage
69.4x
Very solid
Net debt
-5.3Md USD
Equity
31.7Md USD
Closed daily candles, 2 years
Last close on September 24, 2026: 796.02 USD
- MM20802.86
- MM50774.60
- MM200735.26
- RSI 1450.9
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+1.22%
200-day average slope, 3 months
+5.32%
50-day average slope, 1 month
+9.87%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
1.68 % per day
Volatility change
-11.93%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 43.88 (9) | 54.10 (27) | 16 975 (25) | 7 205 (4) | 4 838 (9) |
| 2027 | 50.63 (9) | 60.88 (26) | 18 536 (23) | 7 953 (4) | 5 441 (9) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of September 25, 2026.
Same sub-industry: 431 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ARGX | 7.5 | 6.9 | 59.5Md USD | 36.9x | 32.8 % | 81.8 % | 23.3 % | -4.1x | 1.9 % | 33.9 % | ||
| 2 | VRTX | 6.7 | 5.9 | 131Md USD | 30.0x | 34.7 % | 12.0 % | 21.5 % | -0.9x | 2.9 % | 38.4 % | ||
| 3 | REGN | 6.5 | 5.8 | 82.6Md USD | 19.5x | 27.9 % | 16.7 % | 13.0 % | -1.3x | 4.6 % | 38.2 % | ||
| 4 | AMGN | 6.3 | 6.2 | 220Md USD | 25.2x | 22.9 % | 9.8 % | 14.0 % | 2.9x | 4.6 % | 42.2 % | ||
| 5 | ABBV | 6.2 | 5.6 | 468Md USD | 74.9x | 9.7 % | 10.2 % | 10.5 % | 2.2x | 3.9 % | 19.4 % | ||
| 6 | GILD | 5.5 | 4.3 | 188Md USD | Not meaningful (loss) | -10.6 % | 10.7 % | -8.4 % | 1.1x | 6.9 % | 31.0 % | ||
| 7 | CSL | 4.5 | 4.2 | 60.5Md USD | Not meaningful (loss) | -15.6 % | -2.8 % | -8.9 % | 1.8x | 4.7 % | -9.7 % | ||
| 8 | NTRA | 3.8 | 2.3 | 56.3Md USD | Not meaningful (loss) | -7.1 % | 37.7 % | -11.6 % | 3.9x | 0.1 % | 136.1 % | ||
| 9 | MRNA | 2.7 | 1.9 | 72.7Md USD | Not meaningful (loss) | -141.4 % | 2.1 % | -34.8 % | 1.3x | -1.7 % | 654.5 % |
